A higher number of SARS-COV-2 infections in quilombola communities than in the local population in Brazil

Imagem de Miniatura
Arquivos
art_MARTINS_A_higher_number_of_SARSCOV2_infections_in_quilombola_2023.PDF (1.65 MB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
MARTINS, Aline Fagundes
SOUZA, Daniela Raguer Valadao de
REZENDE NETO, Jose Melquiades de
SANTOS, Aryanne Araujo
INVENCAO, Grazielly Bispo da
MATOS, Igor Leonardo Santos
SANTOS, Kezia Alves dos
JESUS, Pamela Chaves de
SILVA, Francilene Amaral da
ALMEIDA, Fernando Henrique Oliveira de
Citação
FRONTIERS IN PUBLIC HEALTH, v.11, article ID 1095162, 12p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The historical and social vulnerability of quilombola communities in Brazil can make them especially fragile in the face of COVID-19, considering that several individuals have precarious health systems and inadequate access to water. This work aimed to characterize the frequency of SARS-COV-2 infections and the presence of IgM and IgG SARS-CoV-2 antibodies in quilombola populations and their relationship with the presence of risk factors or preexisting chronic diseases in the quilombola communities. We analyzed the sociodemographic and clinical characteristics, serological status, comorbidities, and symptoms of 1,994 individuals (478 males and 1,536 females) from 18 Brazilian municipalities in the State of Sergipe of quilombola communities, which were evaluated at different epidemiological weeks, starting at the 32nd (August 6th) and ending at the 40th (October 3rd) epidemiological week. More than 70% of studied families live in rural areas and they have an extreme poverty social status. Although we found a higher number of SARS-COV-2 infections in quilombola communities than in the local population, their SARS-CoV-2 reactivity and IgM and IgG positivity varied across the communities investigated. Arterial hypertension was the most risk factor, being found in 27.8% of the individuals (9.5% in stage 1, 10.8% in stage 2, and 7.5% in stage 3). The most common COVID-19 symptoms and comorbidities were headache, runny nose, flu, and dyslipidemia. However, most individuals were asymptomatic (79.9%). Our data indicate that mass testing must be incorporated into public policy to improve the health care system available to quilombola populations during a future pandemic or epidemic.
Palavras-chave
anti-SARS-CoV-2 antibodies, COVID-19, quilombola, quilombola communities, risk factors
URI
https://observatorio.fm.usp.br/handle/OPI/54569
Referências
  1. Adil MT, 2021, POSTGRAD MED J, V97, P110, DOI 10.1136/postgradmedj-2020-138386
  2. [Anonymous], PAINEL CONASS COVID
  3. [Anonymous], CERT EXP COM REM QUI
  4. [Anonymous], 2020, SITUACAO QUILOMBOS B
  5. [Anonymous], TOD COR GOV SERG CAN
  6. [Anonymous], OR NOT REG CAS COVID
  7. [Anonymous], ESP COR
  8. [Anonymous], COVID 19 B EP CONAQ
  9. [Anonymous], OBS COVID 19 BR
  10. [Anonymous], MON COVID 19
  11. [Anonymous], COR BRAS
  12. [Anonymous], 2003, DECRETO NO 4887 20 N
  13. Associacao Brasileira de Antropologia, 1995, TERRA DE QUILOMBOS, P1
  14. Bezerra VM, 2015, CIENC SAUDE COLETIVA, V20, P797, DOI 10.1590/1413-81232015203.14342014
  15. Borges LP, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e11368
  16. Borges LP, 2021, LIFE-BASEL, V11, DOI 10.3390/life11111184
  17. Borges LP, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108144
  18. Borges LP, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.108
  19. Bwire G, 2022, BMC MED, V20, DOI 10.1186/s12916-022-02367-4
  20. Celia Barbosa Guedes A., 2020, RES SOC DEV, V9, P1, DOI [10.33448/rsd-v9i7.4352, DOI 10.33448/RSD-V9I7.4352]
  21. Choe JY, 2020, J MED VIROL, V92, P2567, DOI 10.1002/jmv.26060
  22. Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507
  23. Crowe J, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.26447
  24. Mussi RFD, 2019, CIENC SAUDE COLETIVA, V24, P2481, DOI 10.1590/1413-81232018247.13982017
  25. De Marinis Yang, 2020, Infection Ecology & Epidemiology, V10, P1821513, DOI 10.1080/20008686.2020.1821513
  26. Matos CCDA, 2020, REV SAUDE PUBL, V54, DOI 10.11606/s1518-8787.2020054003042
  27. Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
  28. Finlay BB, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2010217118
  29. Flores-Ramirez R, 2021, GLOB PUBLIC HEALTH, V16, P975, DOI 10.1080/17441692.2021.1923777
  30. Gomes NL., 2021, EVEN3 PUBL, V2, P122
  31. Goncalves NV, 2021, J INFECT DEV COUNTR, V15, P1066, DOI 10.3855/jidc.14420
  32. Gray R, 1995, Eur J Surg Oncol, V21, P137, DOI 10.1016/S0748-7983(95)90105-1
  33. Gurgel RQ, 2021, J INFECTION, V82, P206, DOI 10.1016/j.jinf.2020.11.037
  34. IBGE, IBGE PROJ POP
  35. Khani E, 2021, EUR J PHARMACOL, V912, DOI 10.1016/j.ejphar.2021.174582
  36. Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
  37. Ma SM, 2020, INT J INFECT DIS, V96, P683, DOI 10.1016/j.ijid.2020.05.068
  38. Mbembe A., 2016, NECROPOLITICA ARTE E, V2, P122
  39. Soares RDM, 2020, AM J TROP MED HYG, V103, P1184, DOI 10.4269/ajtmh.20-0483
  40. MLA de S., 2020, ZERO A SEIS, V22, P1281, DOI [10.5007/1980-4512.2020V22NESPP1281, DOI 10.5007/1980-4512.2020V22NESPP1281]
  41. Nantong Egens Biotechnology Co, 2020, SER TEST EV REP COVI
  42. Pereira RH., 2019, GITHUB REPOSITORY
  43. Pormohammad A, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2179
  44. Roriz MSR., 2021, RES SOC DEV, V10, pe97101421808, DOI [10.33448/rsd-v10i14.21808, DOI 10.33448/RSD-V10I14.21808]
  45. Rostami A, 2021, CLIN MICROBIOL INFEC, V27, P331, DOI 10.1016/j.cmi.2020.10.020
  46. Rocha PAS, 2022, HEADACHE, V62, P650, DOI 10.1111/head.14319
  47. Santos de Melo M., 2020, MEDRXIV, V24, P20200873, DOI [10.1101/2020.09.24.20200873, DOI 10.1101/2020.09.24.20200873]
  48. Shah P, 2020, ANN MED, V52, P354, DOI 10.1080/07853890.2020.1791356
  49. Silva Thalane Souza Santos, 2016, Cad. saúde colet., V24, P376, DOI 10.1590/1414-462x201600030068
  50. Soares DA, 2014, CAD SAUDE PUBLICA, V30, P341, DOI 10.1590/0102-311X00004613
  51. Sott MK, 2022, INT J HEALTH SERV, V52, P442, DOI 10.1177/00207314221122658
  52. Souza CL, 2014, CIENC SAUDE COLETIVA, V19, P1653, DOI 10.1590/1413-81232014196.08662013
  53. Santos DMS, 2019, ARQ BRAS CARDIOL, V113, P383, DOI 10.5935/abc.20190143
  54. Swets MC, 2022, LANCET, V399, P1463, DOI 10.1016/S0140-6736(22)00383-X
  55. Vera-Ponce VJ, 2021, REV CUERPO MED HOSP, V14, P8, DOI [10.35434/rcmhnaaa.2021.14sup1.1140, 10.35434/rcmhnaaa.2021.14Sup1.1140]
  56. Veran JF, 2013, BRESIL-S, V4, P79, DOI 10.4000/bresils.258
  57. Wickham H., 2016, GGPLOT2 USE R, DOI [10.1007/978-3-319-24277-4, DOI 10.1007/978-3-319-24277-4_1]
  58. Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
  59. Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - LIM/29
Artigos e Materiais de Revistas Científicas - ODS/01
Artigos e Materiais de Revistas Científicas - ODS/03